Osteoporosis Treatment: All Your Options Explained

How is osteoporosis treated?

Osteoporosis is treated by strengthening bones and preventing fractures — through a foundation of lifestyle measures, and, for most people at real risk, a bone-protecting medicine on top. The NHS frames the goal plainly: "treating osteoporosis involves treating and preventing fractures, and using medicines to strengthen bones" NHS. Notice what that does — and doesn't — promise. The aim is fewer broken bones, not a return to youthful bone; our honest look at whether osteoporosis can be reversed explains why that distinction matters.

It helps to think of treatment as a ladder. At the base is everyday lifestyle: enough calcium and vitamin D, the right exercise, stopping smoking and limiting alcohol. The next rung, for most people diagnosed with osteoporosis, is a first-line drug — usually a bisphosphonate. If that isn't suitable, or if your fracture risk is very high, treatment steps up to a different medicine. This article is a map of the whole landscape at hub level; each option links down to a full, sourced deep-dive. It is not a substitute for advice from your GP or specialist, and it does not cover dosing.

What lifestyle changes form the foundation of osteoporosis treatment?

The foundation of every osteoporosis plan is the same set of everyday habits: adequate calcium and vitamin D, weight-bearing and strength exercise, stopping smoking and limiting alcohol. UK guidance is unusually consistent here. The National Osteoporosis Guideline Group (NOGG) makes strong recommendations for a combination of weight-bearing and muscle-strengthening exercise, adequate calcium (a minimum of about 700mg a day), and vitamin D (at least 800IU a day if you are insufficient), alongside stopping smoking, restricting alcohol to no more than two units a day, and having a falls assessment National Osteoporosis Guideline Group (NOGG).

On the nutrition basics, the NHS advises that most adults need 700mg of calcium and 10 micrograms of vitamin D a day NHS. For a food-first walkthrough, see vitamin D, calcium and protein for bone health and how to improve bone density naturally.

Exercise deserves its own mention because the type matters. The Royal Osteoporosis Society recommends combining impact (weight-bearing) exercise with strength (resistance) exercise, which can help "maintain or improve your bone strength" Royal Osteoporosis Society. Crucially, the same source is explicit that "exercise is not a replacement for an osteoporosis medicine" — the two work together Royal Osteoporosis Society. Our guide to the best exercises for bone health sets out what to actually do, and any new high-intensity programme should be discussed with a clinician or specialist physiotherapist first.

What is the first-line drug treatment for osteoporosis?

For most people, the first-line medicine is a bisphosphonate, and alendronate is usually the first one offered. The Royal Osteoporosis Society puts it directly: "alendronate (a bisphosphonate) is usually the first medicine that people are offered. But this may be different for you" Royal Osteoporosis Society. Bisphosphonates work by slowing bone breakdown — the NHS explains they "slow the rate that bone is broken down in your body," which maintains bone density and reduces fracture risk NHS.

They are also formally recommended. NICE states that oral and intravenous bisphosphonates are "recommended, within their marketing authorisations, as options for treating osteoporosis in adults" who have been assessed as being at higher risk of a fragility fracture NICE TA464. The main UK options — alendronate, risedronate and ibandronate as tablets, and zoledronate as a once-a-year infusion — are covered in our guide to bisphosphonates for osteoporosis, with a dedicated deep-dive on alendronic acid and its side effects. Serious side effects are genuinely rare, and treatment is usually reviewed after about five years — more on that below.

What if bisphosphonates aren't suitable?

When bisphosphonates can't be taken or tolerated, the common next step is denosumab, an injection given every six months; HRT and raloxifene are further options mainly for some women after the menopause. The Royal Osteoporosis Society acknowledges that "there are some cases where bisphosphonates may not be suitable," and that some people need to try a different medicine to find one that fits Royal Osteoporosis Society.

Denosumab (brand name Prolia) is a twice-yearly injection that, like bisphosphonates, slows the cells that break bone down — but it works differently and behaves differently when stopped Royal Osteoporosis Society. There is no "drug holiday" with denosumab, and stopping it without a planned follow-on can trigger a rebound in bone loss, which is why our full guide to denosumab (Prolia) stresses the six-monthly schedule. For postmenopausal women who cannot take or tolerate oral bisphosphonates, NICE recommends denosumab as an option NICE TA204.

For some women, hormones are part of the picture. HRT can slow the bone loss that follows menopause and is a recommended option for suitable younger postmenopausal women, particularly those under 60 at high fracture risk Royal Osteoporosis Society — our guide to oestrogen, HRT and bone density covers who it suits. Raloxifene is a related option: the NHS notes it "is the only type of SERM available for treating osteoporosis" and "is only recommended for women, after the menopause" NHS.

What are bone-building (anabolic) treatments, and who are they for?

Bone-building — or "anabolic" — drugs actively stimulate new bone formation, and they are reserved for severe osteoporosis at very high fracture risk rather than used first. Most osteoporosis medicines are anti-resorptive: they defend the bone you have by slowing breakdown. Anabolic drugs do something different — they build. The NHS describes parathyroid hormone treatments such as teriparatide as being "used to stimulate cells that create new bone" NHS.

The other anabolic option is romosozumab (Evenity), which both builds bone and slows breakdown, given as a fixed 12-month course Royal Osteoporosis Society. NICE recommends romosozumab specifically for severe osteoporosis in women after the menopause who are at high risk of fracture and have had a recent major fracture NICE TA791. Because these drugs are reserved for people at imminent, very high risk, they are specialist decisions, given for a set period, and almost always followed by an anti-resorptive drug (usually a bisphosphonate) to preserve the gains. Importantly, romosozumab carries a cardiovascular warning — it is not offered to anyone who has had a heart attack or stroke Royal Osteoporosis Society. Our deep-dive on romosozumab (Evenity) covers eligibility, the 12-month course and that cardiovascular warning in full.

How is the right osteoporosis treatment chosen?

Treatment is matched to your fracture risk, not picked from a menu — the higher your risk, the stronger the case for more intensive treatment. The Royal Osteoporosis Society lists what clinicians weigh up: your age and sex, any previous fractures, other medical conditions, the types and forms of medicine available, and your own thoughts and feelings about treatment Royal Osteoporosis Society.

Fracture risk itself is usually estimated with a tool such as FRAX, alongside a bone density scan — our guide to fracture risk and FRAX explained walks through how that number is worked out and what it means. In practice, this is why treatment is described as first-line versus escalation: most people begin with lifestyle plus a bisphosphonate, move to denosumab or another option if that isn't suitable, and are considered for a bone-building drug only if their risk is very high. NICE is clear that the choice "should be made on an individual basis" between you and your clinician, weighing the advantages and disadvantages of each option NICE TA464.

How is osteoporosis treatment monitored and reviewed?

Because you cannot feel your bones getting stronger, treatment is monitored by measuring bone density over time, reviewing medicines periodically, and — for bisphosphonates — considering a planned pause after about five years. A bone density scan is normally repeated every two to five years, because bone changes slowly and scans done too close together show little difference Royal Osteoporosis Society.

Two features of monitoring are worth knowing. First, the drug holiday: because bisphosphonates keep working for a while after you stop, some people are advised to pause after around five years — a decision that depends on where your bone density actually stands, which our bisphosphonates guide explains. This does not apply to denosumab, which needs a planned follow-on rather than a pause. Second, some clinics use bone turnover markers — blood tests that can give an earlier read on whether an anti-resorptive medicine is working; our guide to bone turnover markers covers what they can and can't tell you. Ultimately, the honest measure of success is the trend, which is why tracking bone density matters as much as the starting number — the theme of our article on whether osteoporosis can be reversed.

Where does a bone scan fit into your treatment plan?

Every step above — deciding whether to treat, which drug to start, when to escalate, and whether it's working — hinges on measuring your bone density, so being able to do that safely and repeatedly is genuinely useful. Standard DEXA uses a small X-ray dose. REMS (Radiofrequency Echographic Multi Spectrometry) is radiation-free, so it can be repeated to establish a baseline and follow how your bone health changes over time. It complements — rather than replaces — your GP's or specialist's plan and any decision about starting, pausing or switching treatment.

If you want to know your starting point or keep an eye on the trend alongside your clinical care, you can book a radiation-free bone health assessment or read more about our bone health assessment. Decisions about diagnosis and medicines always remain with your GP or specialist.

---

This article is for general information and is not a substitute for advice from your GP, pharmacist or specialist — never start, stop or change a prescribed medicine on your own. It is part of our bone health series; for the deep-dives, see bisphosphonates, denosumab (Prolia) and romosozumab (Evenity).